Royal Bank of Canada Has $8.56 Million Stake in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Royal Bank of Canada increased its Jazz Pharmaceuticals stake by 17.4% in the first quarter, owning 45,251 shares valued at approximately $8.56 million. Institutional investors and hedge funds collectively hold 89.14% of JAZZ shares.
• Jazz Pharmaceuticals reported quarterly revenue of $1.21 billion, up 15.5% year over year and above estimates, although adjusted EPS of $5.71 missed consensus by $0.47. Analysts expect $21.62 in EPS for the current fiscal year.
• Investor sentiment remains broadly positive, with the stock trading near its 52-week high and a consensus “Moderate Buy” rating supported by a $272.74 price target; however, planned withdrawal of the Zepzelca indication and recent insider selling represent risks.

Royal Bank of Canada grew its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 17.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 45,251 shares of the specialty pharmaceutical company's stock after buying an additional 6,695 shares during the period. Royal Bank of Canada owned approximately 0.07% of Jazz Pharmaceuticals worth $8,556,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of JAZZ. LRI Investments LLC bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at about $38,000. Danske Bank A S bought a new position in Jazz Pharmaceuticals during the 3rd quarter worth approximately $40,000. Geneos Wealth Management Inc. grew its holdings in Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company's stock valued at $47,000 after purchasing an additional 137 shares during the period. Caitong International Asset Management Co. Ltd grew its holdings in Jazz Pharmaceuticals by 1,383.3% during the third quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company's stock valued at $47,000 after purchasing an additional 332 shares during the period. Finally, Leonteq Securities AG bought a new stake in Jazz Pharmaceuticals in the fourth quarter valued at approximately $50,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $256.56 on Monday. The firm has a market cap of $16.65 billion, a PE ratio of 17.69, a P/E/G ratio of 0.23 and a beta of 0.32. The business's 50 day simple moving average is $241.29 and its 200 day simple moving average is $209.80. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.58 and a current ratio of 1.78. Jazz Pharmaceuticals PLC has a 52-week low of $109.87 and a 52-week high of $265.05.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing analysts' consensus estimates of $6.18 by ($0.47). The firm had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.The company's revenue was up 15.5% compared to the same quarter last year. During the same period last year, the company earned ($8.25) EPS. On average, analysts predict that Jazz Pharmaceuticals PLC will post 21.62 earnings per share for the current fiscal year.

Key Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz’s quarterly revenue reached $1.21 billion, beating consensus expectations of $1.11 billion and increasing 15.5% year over year. Management also raised its 2026 revenue outlook to $4.60 billion-$4.75 billion, supported by its neuroscience and oncology businesses. What Does Jazz Pharmaceuticals Raised Guidance Mean
• Positive Sentiment: The company’s oxybate franchise, including Xywav, continues to post double-digit growth despite generic Xyrem competition, helping support confidence in the upgraded outlook.
• Positive Sentiment: Analyst sentiment has strengthened. Wells Fargo raised its price target to $300 and maintained an overweight rating, while Morgan Stanley lifted its target to $280. Other firms, including JPMorgan, Needham and Bank of America, also maintain bullish ratings or targets above the recent trading range. Wells Fargo Gives Jazz Pharmaceuticals a Buy
• Positive Sentiment: Ziihera, or zanidatamab, remains a potential catalyst, with an FDA decision expected August 25 for first-line gastroesophageal adenocarcinoma. Approval could expand Jazz’s oncology revenue base.
• Positive Sentiment: Recent coverage describes JAZZ as a strong long-term momentum and value candidate, reflecting its improving earnings outlook and stock performance near its 52-week high. Why Jazz Pharmaceuticals Is a Top Momentum Stock
• Neutral Sentiment: Adjusted earnings per share were $5.71, below the $6.18 consensus estimate. The revenue beat and higher guidance offset the earnings miss, but margins and future profitability remain important risks.
• Negative Sentiment: Jazz plans to seek FDA withdrawal of the second-line lurbinectedin, marketed as Zepzelca, indication for small-cell lung cancer. The move removes a potential regulatory catalyst and underscores pressure on the product’s development prospects. Jazz Seeks FDA Withdrawal of Lurbinectedin Indication
• Negative Sentiment: Director Bruce Cozadd sold 6,000 shares for approximately $1.52 million. The transaction occurred under a pre-arranged Rule 10b5-1 plan and reduced his position by only 1.64%, making it a limited negative signal. Jazz Pharmaceuticals Director Share Sale

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on JAZZ shares. Canaccord Genuity Group assumed coverage on shares of Jazz Pharmaceuticals in a research report on Thursday, July 16th. They set a "buy" rating and a $290.00 price target on the stock. Bank of America upped their price objective on shares of Jazz Pharmaceuticals from $281.00 to $307.00 and gave the company a "buy" rating in a research report on Wednesday, June 10th. TD Cowen raised their price objective on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the stock a "buy" rating in a research note on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a $287.00 target price on shares of Jazz Pharmaceuticals in a report on Tuesday, August 4th. Finally, Sanford C. Bernstein restated a "market perform" rating on shares of Jazz Pharmaceuticals in a report on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $272.74.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, Director Mark Douglas Smith sold 1,157 shares of Jazz Pharmaceuticals stock in a transaction on Monday, June 15th. The shares were sold at an average price of $230.55, for a total value of $266,746.35. Following the sale, the director directly owned 9,680 shares in the company, valued at approximately $2,231,724. The trade was a 10.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $252.98, for a total transaction of $1,517,880.00. Following the transaction, the director owned 360,682 shares of the company's stock, valued at approximately $91,245,332.36. This represents a 1.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 19,098 shares of company stock valued at $4,649,786 in the last quarter. Company insiders own 4.10% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source